A groundbreaking gene-editing treatment could offer a potential cure for high cholesterol, as demonstrated by a small-scale clinical trial unveiled on Saturday. The new drug, delivered through a one-time injection, reduced both“bad” LDL cholesterol and triglycerides by approximately 50%, showing no discernible side effects after two months of observation.

Cholesterol, a waxy substance found in the blood, exists in two forms: low-density lipoprotein, often termed“bad” cholesterol, and high-density lipoprotein, the“good” variety. LDL is known to contribute to plaque formation on the walls of blood vessels, a condition that can lead to heart disease, one of the leading causes of death worldwide. Triglycerides, another form of fat found in the bloodstream, are also linked to increased heart disease risks when elevated.

The new treatment, based on CRISPR gene-editing technology, works by targeting and disabling a specific gene-ANGPTL3-which is responsible for producing both LDL cholesterol and triglycerides. This breakthrough builds upon the discovery that a small percentage of the population, roughly 1 in 300 people, carries a genetic mutation that naturally disables this gene. These individuals exhibit a significantly lower risk of heart disease, despite having high cholesterol levels.

The clinical trial, although small, revealed significant results. Participants who received the gene-editing injection showed a dramatic reduction in LDL and triglyceride levels. The medication functions by essentially turning off the ANGPTL3 gene, which prevents the body from producing these harmful substances. Within two months, patients experienced an average reduction of 50% in these levels, with no immediate adverse effects observed. Experts suggest that these findings could pave the way for a revolutionary treatment option, particularly for those who suffer from familial hypercholesterolemia, a genetic condition that results in extremely high cholesterol levels from birth.

This new approach offers hope to millions of individuals with high cholesterol, particularly those who do not respond well to conventional treatments such as statins. Statins, which are widely prescribed to lower cholesterol, work by inhibiting the liver's production of cholesterol. However, they can cause side effects such as muscle pain, digestive issues, and liver damage, making them unsuitable for some patients. The gene-editing drug bypasses the need for long-term medication, potentially providing a one-time solution to managing high cholesterol.

While the trial results are promising, the drug is still in the early stages of development, and further research is needed before it becomes widely available. The small sample size of the trial has led to some calls for caution, as larger studies will be necessary to confirm the long-term safety and efficacy of the treatment. Additionally, experts caution that the full implications of gene-editing therapies are not yet fully understood, and regulatory bodies will need to thoroughly assess the risks before approving such treatments for general use.

The potential to eliminate the need for lifelong cholesterol management could be a game-changer for patients with high cholesterol. With cardiovascular disease remaining the leading cause of death globally, innovative treatments that target the root causes of these conditions are of immense interest to the medical community.

Notice an issue? Arabian Post strives to deliver the most accurate and reliable information to its readers. If you believe you have identified an error or inconsistency in this article, please don't hesitate to contact our editorial team at editor[at]thearabianpost[dot]com. We are committed to promptly addressing any concerns and ensuring the highest level of journalistic integrity.

MENAFN10112025000152002308ID1110322299